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COST-UTILITY ANALYSIS OF THE TREATMENT
OF RELAPSING-REMITTING MULTIPLE
SCLEROSIS WITH GLATIRAMER ACETATE OR
INTERFERON BETA IN SPAIN
Rubio-Terrés C1, Medina F2,Aristegui I1, Izquierdo G2
1Aventis Pharma, S.A, Madrid, Spain; 2Hospital Universitario
Virgen Macarena, Sevilla, Spain
OBJECTIVE: To carry out a cost-utility analysis of 
the treatment of relapsing-remitting multiple sclerosis
(RRMS) with glatiramer acetate (Copaxone) or interferon
beta products (all as a whole, Avonex, Rebif and
Betaferon). METHODS: Markov pharmacoeconomic
model that compared treatments by simulating the life 
of a hypothetical cohort of 30-year-old women, from 
the societal perspective. Transition probabilities, utilities,
resource utilization and costs (direct and indirect) were
estimated from Spanish sources and bibliography. Simple
univariate sensitivity analyses of the base case were per-
formed. RESULTS: In the base case analysis, the average
cost per patient (€ in 2001) of life treatment, considering
a life expectancy of 53 years, would be €1,243,906
€1,818,149, €1,763,263, €1,987,153 and €1,704,031
with Copaxone, all the interferons, Avonex, Rebif and
Betaferon, respectively. Thus, the savings with Copaxone
would range from €460,000 to €737,000 approximately.
The quality-adjusted life years (QALY) obtained with
Copaxone or the interferons would be 10.977 and 6.917,
respectively, with a mean gain of 4.060 QALY/patient
with Copaxone. Sensitivity analyses conﬁrmed the
robustness of the base case. Interferons would be supe-
rior to Copaxone only in the hypothetical and unlikely
case that they delay the progression of the illness by 20%
more than that presently observed in the clinical trials.
CONCLUSIONS: For a typical patient with RRMS,
treatment with Copaxone would be more efﬁcient than
interferons, which would be dominated by the former
(Copaxone would be more effective with lower costs than
the latter).
PNP16
THE COMPARISON OF DIFFERENT METHODS
FOR DETERMINING THE IMPACT OF MIGRAINE
PROPHYLAXIS ON COSTS
Barlev A1, Globe D1,Wu EQ2,Yu W3, Johnson KA1
1University of Southern California, Los Angeles, CA, USA;
2Analysis Group/Economics, Boston, MA, USA; 3WellPoint
Pharmacy Management, West Hills, CA, USA
OBJECTIVES: Compare different approaches to assess-
ing the association of prophylactic treatment and total
migraine-speciﬁc costs from administrative data. Evalu-
ate the usefulness of propensity scores. METHODS:
Using retrospective, administrative data, two groups of
patients were identiﬁed: 1) received prophylactic migraine
treatment; and 2) potential candidates for prophylaxis.
Four methods were applied to compare the log of the total
migraine cost between the groups, and to determine the
association of prophylaxis with total cost. In the ﬁrst
method, groups were matched based on logit propensity
score to adjust for selection bias. In the second, groups
were exact case matched on the same variables. In the
third method a linear regression model was constructed
using all observations in the data. A comparison between
the means of total migraine cost, and log of total migraine
cost was also evaluated based on a T-test without adjust-
ment for selection bias. Jackknife residual analysis was
performed, and statistically signiﬁcant outliers were elim-
inated. RESULTS: As typical for cost data, the total
migraine cost data was skewed, so the data was log trans-
formed. Results based on different methods showed the
same trend; patients treated with migraine prophylaxis
had lower total migraine cost. Mean differences (p-value)
in total migraine cost and log cost, between the groups,
without adjustment for selection bias, were $263
(0.0306) and 0.3192 (<0.0001). Log total migraine cost
showed a 29% (<0.0001) (linear regression), 33.5%
(<0.0001) (propensity scores method), and 29.6%
(<0.0001) (case matched method) reduction in cost for
those on prophylaxis. CONCLUSION: The construction
of a propensity score model is more complicated and may
result in some data loss. The ability of the model to adjust
for selection bias depends on how well the propensity
score model predicts the treatment variable. The con-
straints in this retrospective, administrative data limit the
usefulness of this approach.
PNP17
THE ECONOMIC BURDEN OF MIGRAINE AND
COMORBID MENTAL CONDITIONS: RESULTS
FROM A CASE-CONTROL STUDY
Pesa JA1, Lage MJ2
1AstraZeneca LP, Wilmington, DE, USA; 2HealthMetrics
Outcomes Research, L.L.C, Groton, CT, USA
OBJECTIVES: To examine the direct and indirect costs
for adults diagnosed with migraine, as well as the costs
associated with comorbid anxiety and/or depression.
METHODS: Individuals diagnosed with migraine or
receiving a migraine medication between 1999–2000
were identiﬁed in a database capturing inpatient, outpa-
tient, and prescription drug services from approximately
45 large employers. The migraine cohort (N = 2519) was
matched to a non-migraine cohort (N = 2519) at a 1 :1
ratio based upon age, gender and metropolitan statistical
area. Variables of interest included direct medical costs
(inpatient, outpatient, and prescription drug) as well as
indirect costs (absenteeism, short-term disability and
worker compensation). RESULTS: Adults with migraine
had signiﬁcantly higher inpatient (p = 0.0008), outpatient
(p < 0.0001), prescription drug (p < 0.0001), and overall
medical costs (p < 0.0001) compared to the non-migraine
cohort. In addition, adults with migraine had signiﬁcantly
higher costs associated with absenteeism (p = 0.0010)
compared to the healthy cohort. The presence of depres-
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sion (N = 556) or anxiety (N = 158) in addition to
migraine equated to signiﬁcantly greater outpatient, pre-
scription drug, and total medical costs compared to a
healthy comparator group. The differential in total costs
(medical plus productivity) between migraine sufferers
with comorbid anxiety ($4562, p < 0.0001) or comorbid
depression ($6193, p < 0.0001) and the healthy cohort
was substantially greater than the differential between
migraine sufferers without these comorbidities and their
healthy matches ($3638, p < 0.0001). CONCLUSIONS:
These results demonstrate and quantify the economic
burden in terms of direct and indirect costs to employers
of migraine alone and migraine in conjunction with
depression or anxiety.
PNP18
ECONOMIC COMPARISON OF FIVE TRIPTAN
STRATEGIES FOR MIGRAINE HEADACHES
USING MONTE CARLO SIMULATION
Bell CF, Hu X, Markson L
Merck & Co, Inc, West Point, PA, USA
OBJECTIVE: To assess, via Monte Carlo simulation, the
per-attack drug acquisition cost and effectiveness (pro-
portion of patients pain-free two hours post-dose) of ﬁve
oral triptan strategies for treatment of acute migraine
headaches. METHODS: A Monte Carlo simulation
model was used to estimate the average number of
patients needed to treat (NNT), relative to placebo, to
achieve the efﬁcacy endpoint of one pain-free two hours
post-dose (pain-free patient). Efﬁcacy data was obtained
from a published meta-analysis of 53 triptan-speciﬁc 
clinical trials. A normal distribution for the proportion of
pain-free patients was used and was based on the means
and 95% conﬁdence intervals reported in the meta-
analysis. Single-dose acquisition costs, based on average
wholesale prices (2002US$), were applied to the NNT
results, allowing for a per-attack assessment of the cost
per pain-free patient. Oral triptans almotriptan, nara-
triptan, rizatriptan, sumatriptan and zolmitriptan were
assessed in the simulation. RESULTS: After 10,000 
iterations, the mean NNT (95% CI) to achieve one 
pain-free patient was 3.31 (2.97–3.71) for rizatriptan,
4.16 (2.83–6.54) for zolmitriptan, 5.06 (3.32–8.53) for
almotriptan, 5.14 (4.50–5.92) for sumatriptan and 7.26
(5.52–9.96) for naratriptan. The mean cost (95% CI) per
pain-free patient was $55.61 ($36.50–$93.70), $56.60
($50.81–$63.44), $75.34 ($51.34–$118.61), $88.27
($77.28–$101.70) and $145.27 ($110.38–$199.27) for
almotriptan, rizatriptan, zolmitriptan, sumatriptan and
naratriptan, respectively. Cost differences between
almotriptan and rizatriptan were relatively small, with 
38 percent of simulations resulting in cost savings per
pain-free patient favoring rizatriptan. CONCLUSIONS:
Inasmuch as the results suggested that almotriptan and
rizatriptan may be similar on a cost per pain-free patient
basis, the NNT results favored rizatriptan, with approx-
imately two fewer patients needed to treat to achieve one
pain-free patient. Future economic assessments, including
endpoints such as tablet consumption per attack and 
consistency across multiple attacks, may provide further
guidance as to the most cost-effective triptan strategies.
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COST PER SUCCESSFULLY TREATED PATIENT
AS MEASURE OF EFFECTIVENESS IN
COMPARING ELETRIPTAN TO SUMATRIPTAN
Weis KA
Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: Use the outcomes effectiveness measure 
of a successfully treated patient to compare the cost-
effectiveness of Eletriptan to Sumatriptan. METHODS:
Data for the economic analysis was based on pooled data
from three randomized, double blind, placebo-controlled
phase III/B clinical trials. Logistic regression with SAS
GENMOD was used to ﬁt the model and the CON-
TRAST statement was used for the comparisons of inter-
est—the numbers of successfully treated patients. Three
measure of success were analyzed: patients with headache
response within 2 hours of triptan therapy, sustained to
24 hours; patients with headache response within 1 hour
of triptan therapy, sustained to 24 hours, and patients
who were pain free within 2 hours of triptan therapy, sus-
tained to 24 hours. The cost-effectiveness measure—cost
per successfully treated patient—was calculated as a ratio
of the total cost of treating all patients to the number 
of successfully treated patients for the comparison of
Eletriptan 40mg vs. Sumatriptan 100mg. The 95% con-
ﬁdence interval for the comparison group for each
outcome effectiveness measure was calculated by boot-
strapping techniques. RESULTS: The number of success-
fully treated patients for each of the 3 outcome measures
of effectiveness was statistically signiﬁcantly greater in the
Eletriptan 40mg groups compared to the Sumatriptan
100mg groups (P-values all =<.002). The 95% conﬁdence
interval ranges for each of the Eletriptan cost-
effectiveness results are smaller and the one for the 2-hour
pain free sustained measure does not overlap that of
Sumatriptan. CONCLUSIONS: The cost per successfully
treated patient is a new composite outcome measure 
of cost-effectiveness that was consistently lower for all
patients treated with Eletriptan 40mg compared to 
Sumatriptan 100mg. Cost-effectiveness using this
outcome measure empirically demonstrates the value for
the resources spent on migraine therapy.
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COST UTILITY ANALYSIS OF
IMMUNOGLOBULINS (IVIG) VERSUS PLASMA
EXCHANGE (PE) FOR THE TREATMENT OF
GUILLAIN BARRE SYNDROME (GBS)
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